{"id":"W4414089879","doi":"10.1016/j.clgc.2025.102431","title":"CABOSEQ 3—Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Therapure Biopharma (Canada); Institute of Cancer Research; Alberta Cancer Foundation; University of Calgary","funders":"Ipsen; Ipsen Biopharmaceuticals","keywords":"Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Metastatic melanoma; Emulation; Clinical trial; Expanded access","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001675098,0.000668359,0.00189513,0.0003498386,0.0003859441,0.00008427022,0.001146643,0.0001428711,0.000292458],"category_scores_gemma":[0.0009569871,0.0005459688,0.0008777134,0.0007066295,0.0003843767,0.0003440633,0.0008191393,0.0008041058,0.00001045366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005223865,"about_ca_system_score_gemma":0.002219186,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008154854,"about_ca_topic_score_gemma":0.003752251,"domain_scores_codex":[0.9931719,0.0006799981,0.002926488,0.001494031,0.001003119,0.0007244122],"domain_scores_gemma":[0.9893657,0.006197433,0.001413587,0.002188171,0.0005005235,0.0003346063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4576174,0.01185744,0.4441954,0.001576302,0.006200036,0.001622514,0.001031206,0.007039432,0.01587902,0.00008181293,0.04737529,0.005524189],"study_design_scores_gemma":[0.4934845,0.01087144,0.1380518,0.0013056,0.03040729,0.00002184043,0.002627898,0.2281887,0.06786024,0.0003121057,0.02478241,0.002086185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817023,0.002967577,0.001608858,0.001064577,0.004548511,0.003163315,0.004103245,0.00005516277,0.0007864836],"genre_scores_gemma":[0.9744998,0.0001614886,0.01580146,0.0002353079,0.001876536,0.00025093,0.006018089,0.00009719512,0.001059237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3061436,"threshold_uncertainty_score":0.9996992,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.282927175586458,"score_gpt":0.4596656794035395,"score_spread":0.1767385038170814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}